SNS-595 and methods of using the same

1. A method for treating cancer comprising administering to a human patient having cancer (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in a dose of about 10 mg/m 2 -100 mg/m 2 and a therapeutically effective amount of cytarabine.

2. The method of claim 1 , wherein the dose is about 30 mg/m 2 -75 mg/m 2 .

3. The method of claim 1 , wherein the dose is about 40 mg/m 2 -80 mg/m 2 .

4. The method of claim 1 , wherein the dose is about 50 mg/m 2 -90 mg/m 2 .

5. The method of claim 1 , wherein the amount of cytarabine administered to the patient is at least 100 mg/m 2 .

6. The method of claim 2 , wherein the amount of cytarabine administered to the patient is at least 100 mg/m 2 .

7. The method of claim 3 , wherein the amount of cytarabine administered to the patient is at least 100 mg/m 2 .

8. The method of claim 4 , wherein the amount of cytarabine administered to the patient is at least 100 mg/m 2 .

9. The method of claim 1 , wherein the cancer is leukemia.

10. The method of claim 4 , wherein the cancer is leukemia.

11. The method of claim 1 , wherein the cytarabine is administered intravenously.